Display options
Cite
Frosch ZAK, Namoglu EC, Mitra N, et al. Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. JCO Oncol Pract. 2021;OP2100312doi: 10.1200/OP.21.00312.
Frosch, Z. A. K., Namoglu, E. C., Mitra, N., Landsburg, D. J., Nasta, S. D., Bekelman, J. E., Iyengar, R., Guerra, C. E., & Schapira, M. M. (2021). Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. JCO oncology practice, OP2100312. https://doi.org/10.1200/OP.21.00312
Frosch, Zachary A K, et al. "Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race." JCO oncology practice vol. (2021): OP2100312. doi: https://doi.org/10.1200/OP.21.00312
Frosch ZAK, Namoglu EC, Mitra N, Landsburg DJ, Nasta SD, Bekelman JE, Iyengar R, Guerra CE, Schapira MM. Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. JCO Oncol Pract. 2021 Sep 15;OP2100312. doi: 10.1200/OP.21.00312. Epub 2021 Sep 15. PMID: 34524837.
Copy Download .nbib Format: NLM
Share it on

JCO Oncol Pract. 2021 Sep 15;OP2100312. doi: 10.1200/OP.21.00312. Epub 2021 Sep 15.

Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race.

JCO oncology practice

Zachary A K Frosch, Esin C Namoglu, Nandita Mitra, Daniel J Landsburg, Sunita D Nasta, Justin E Bekelman, Raghuram Iyengar, Carmen E Guerra, Marilyn M Schapira

Affiliations

  1. Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  2. Penn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  3. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA.
  4. Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  5. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  6. Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  7. Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  8. Marketing Department, The Wharton School, University of Pennsylvania, Philadelphia, PA.
  9. Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  10. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  11. Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, PA.

PMID: 34524837 DOI: 10.1200/OP.21.00312

Abstract

PURPOSE: Patients weigh competing priorities when deciding whether to travel to a cellular therapy center for treatment. We conducted a choice-based conjoint analysis to determine the relative value they place on clinical factors, oncologist continuity, and travel time under different post-treatment follow-up arrangements. We also evaluated for differences in preferences by sociodemographic factors.

METHODS: We administered a survey in which patients with diffuse large B-cell lymphoma selected treatment plans between pairs of hypothetical options that varied in travel time, follow-up arrangement, oncologist continuity, 2-year overall survival, and intensive care unit admission rate. We determined importance weights (which represent attributes' value to participants) using generalized estimating equations.

RESULTS: Three hundred and two patients (62%) responded. When all follow-up care was at the center providing treatment, plans requiring longer travel times were less attractive (

CONCLUSION: Reducing travel burden through shared follow-up may increase patients' willingness to travel to receive cellular therapies, but additional measures are required to facilitate equitable access.

Publication Types

Grant support